Axsome Therapeutics (AXSM) director exercises 6,250 options and holds shares

Rhea-AI Filing Summary

Axsome Therapeutics, Inc. director Mark Coleman reported exercising stock options and holding the resulting shares. On February 23, 2026, he exercised options covering 6,250 shares of common stock at $4.95 per share for cash, and kept the underlying shares rather than selling them. Following these transactions, he directly owned 72,140 shares of Axsome common stock and indirectly beneficially owned 403,856 shares held through an entity over which he has voting and dispositive power.

Insider Trade Summary

6,250 shares exercised/converted

Mixed 3 txns

Insider Coleman Mark

Role Director

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	6,250	$0.00	--
Exercise	Common Stock	6,250	$4.95	$31K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 7,721 shares (Direct); Common Stock — 72,140 shares (Direct); Common Stock — 403,856 shares (Indirect, See Footnote)

Footnotes (1)

1. Represents the exercise of stock options, prior to the 10-year expiration date, for cash and hold of underlying shares. Such shares are held by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coleman Mark

(Last) (First) (Middle)

C/O AXSOME THERAPEUTICS, INC.

ONE WORLD TRADE CENTER, 29TH FLOOR

(Street)

NEW YORK NY 10007

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Axsome Therapeutics, Inc. [ AXSM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/23/2026		M(1)		6,250	A	$4.95	72,140	D
Common Stock								403,856	I	See Footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.95	02/23/2026		M(1)			6,250	03/15/2018	03/15/2027	Common Stock	6,250	$0	7,721	D

Explanation of Responses:

1. Represents the exercise of stock options, prior to the 10-year expiration date, for cash and hold of underlying shares.

2. Such shares are held by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares.

	/s/ Nick Pizzie, Attorney-in-Fact	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Axsome Therapeutics (AXSM) director Mark Coleman report?

Mark Coleman reported exercising stock options for Axsome Therapeutics common stock and holding the resulting shares. The Form 4 shows a derivative exercise on February 23, 2026, rather than an open-market purchase or sale, increasing his directly held common stock position.

How many Axsome Therapeutics (AXSM) stock options did Mark Coleman exercise?

Mark Coleman exercised stock options covering 6,250 shares of Axsome Therapeutics common stock. The options were exercised prior to their 10-year expiration date for cash, and the underlying 6,250 shares were held instead of being immediately sold in the market.

What exercise price did Mark Coleman pay for his Axsome Therapeutics (AXSM) options?

The exercised Axsome Therapeutics stock options carried an exercise price of $4.95 per share. According to the filing, the options were exercised for cash and the underlying shares were retained, indicating this was a cash exercise and hold rather than a cashless or sell-to-cover transaction.

How many Axsome Therapeutics (AXSM) shares does Mark Coleman own directly after the transaction?

After the reported option exercise, Mark Coleman directly owned 72,140 shares of Axsome Therapeutics common stock. This direct holding figure comes from the post-transaction balance shown for his non-derivative common stock position in the Form 4 insider ownership table.

What is Mark Coleman’s indirect ownership in Axsome Therapeutics (AXSM) shares?

Mark Coleman is reported as the indirect beneficial owner of 403,856 Axsome Therapeutics shares. These shares are held by an entity over which he has voting and dispositive power, so they are attributed to him as indirect beneficial ownership under the Form 4 disclosure rules.

Did Mark Coleman sell any Axsome Therapeutics (AXSM) shares in this Form 4 filing?

The Form 4 does not report any sale transactions by Mark Coleman. It describes an exercise of stock options for 6,250 shares, done for cash with a hold of the underlying shares, indicating no concurrent disposition of Axsome Therapeutics common stock in this filing.